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Osteoporosis is a highly prevalent chronic aging-related disease that frequently is only
detected after fracture. We hypothesized that aminobutyric acids could serve as biomarkers
for osteoporosis. We developed a quick, accurate, and sensitive screening method for ami-
nobutyric acid isomers and enantiomers yielding correlations with bone mineral density
(BMD) and osteoporotic fracture. In serum, γ-aminobutyric acid (GABA) and (R)-3-ami-
noisobutyric acid (D-BAIBA) have positive associations with physical activity in young lean
women. D-BAIBA positively associated with hip BMD in older individuals without osteo-
porosis/osteopenia. Lower levels of GABA were observed in 60–80 year old women with
osteoporotic fractures. Single nucleotide polymorphisms in seven genes related to these
metabolites associated with BMD and osteoporosis. In peripheral blood monocytes, dihy-
dropyrimidine dehydrogenase, an enzyme essential to D-BAIBA generation, exhibited positive
association with physical activity and hip BMD. Along with their signaling roles, BAIBA and
GABA might serve as biomarkers for diagnosis and treatments of osteoporosis.
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Osteoporosis, one of the most prevalent chronic aging-related bone diseases, often goes undetected until the firstfragility fracture occurs, causing patient suffering, high
healthcare costs and societal burden. Aminobutyric acids are a
physiologically relevant class of nonproteinogenic amino acids
due to their production from different organs and their potential
roles in health and disease. Aminobutyric acids comprise three
type of isomers: α-aminobutyric acid (AABA), β-aminobutyric
acid (BABA), and γ-aminobutyric acid (GABA). Moreover, pairs
of mirror-image isomers with the same molecular weights and
related structures, also known as enantiomers, including (R)- and
(S)-2-aminobutyric acid (D- and L-AABA), (R)- and (S)-3-ami-
nobutyric acid (D- and L-BABA), and (R)- and (S)-3-aminoiso-
butyric acid (D- and L- BAIBA), have been identified in this class
of molecules. These enantiomers have identical physical and
chemical properties in anisotropic environments, but can have
different biological actovotoes.
AABA has been investigated as a general biomarker of various
conditions such as alcoholic liver injury, sepsis, malnutrition, and
multiple organ failure1–3. Elevated plasma AABA is also linked to
tuberculosis and many pediatric metabolic diseases like Reye’s
syndrome, etc3. BABA is a natural product of plants controlled by
the plant’s immune system important for the treatment of various
plant diseases4; however, there are no associations between BABA
and human diseases. GABA is a major inhibitory neuro-
transmitter in the central nervous system that regulates com-
munication between neurons, and it is implicated in behavior,
cognition, oxidative stress, glucose tolerance, and pathological
conditions such as Alzheimer’s disease and diabetes5,6. Studies in
MCK-PGC1α (muscle-specific overexpression of peroxisome
proliferator-activated receptor gamma coactivator 1-α) mice
demonstrated that GABA levels in both plasma and skeletal
muscles significantly increased following exercise. GABA may
function as a PGC1α-mediated myokine and play an important
role in the release of growth hormone in adaptive response to
exercise7.
L-BAIBA is produced from valine through a mitochodrial
enzyme 4-aminobutyrate aminotransaminase (ABAT)8.
D-BAIBA is produced in the cytosol of liver and kidney from
thymine in a metabolic pathway involving dihydropyrimidine
dehydrogenase (DPYD), dihydropyrimidinase (DPYS), and
β-ureidopropionase (UPB1)9,10. Some amount of L-BAIBA and
D-BAIBA can convert to each other via the stereo-isomerization
reaction between their metabolites, L-methylmalonate semi-
aldehyde (L-MMS) and D-methylmalonate semialdehyde (D-
MMS), through enzymatic or nonenzymatic mechanisms11. But
to date this conversion process has not been described clearly. A
previous study reported that BAIBA attenuates insulin resistance,
suppresses inflammation, and induces fatty acid oxidation via the
AMP-activated protein kinase (AMPK) and peroxisome
proliferator-activated receptor δ (PPARδ) signaling pathway in
skeletal muscle12. BAIBA levels increase in circulation in response
to exercise, thus it serves as a contraction-induced myokine that
increases energy expenditure and participates in exercise-induced
protection from metabolic diseases like type 2 diabetes13–15.
However, the distribution of L- and D- BAIBA is contradictory as
most studies report total BAIBA9.
A major limitation of the aforementioned studies is that none
of these molecules were completely separated and directly
quantified, but relied on derivatizations and deconvolutions. The
importance of the effects of stereoselectivity in biological func-
tions cannot be underscored. Mirror-image enantiomers can
exhibit significanlty different biological potencies, dose–response
relationship, and toxicity. For example, R-thalidomide has been
reported to be responsible for sedative effects, but its
S-enantiomer and related derivatives were linked to teratogenic
effects16. During the period of 2010–2014, 81 of 127 new mole-
cular entities (NMEs) approved by the Food and Drug Admin-
istration (FDA) in the United States were chiral17. Moreover,
77 single enantiomers were the major component among these 81
chiral NMEs17. This stereoselectivity was also observed among
the isomeric aminobutyric acids. In comparison with D-BAIBA,
L-BAIBA was 100–1000 times more potent in protecting osteo-
cytes from reactive oxygen species (ROS)-induced cell death, was
shown to signal through the Mas-Related G Protein-Coupled
Receptor Type D (MRGPRD), was secreted by contracted muscle
from C57Bl/6 mice, and maintained osteocyte viability and
reduced both bone and muscle loss due to hindlimb unloading of
mice18. Thus, in mice the L-enantiomer of BAIBA might act as
the enantiomer secreted by muscle that activates MRGPRD sig-
naling in bone in mice. Therefore, identification and quantifica-
tion of isomeric aminobutyric acids including all single
enantiomers in circulation/tissues is necessary to elucidate the
molecular mechanisms underlying their biological activities, and
may provide a better understanding in the diagnosis and potential
treatments for the related diseases.
In comparison with other techniques, liquid chromatography–
mass spectrometry (LC-MS) is more selective and sensitive, and
therefore, has been widely used as a major analytical approach for
bioanalysis. But the current quantification methods for aminobu-
tyric acid isomers/enantiomers using LC-MS are typically com-
promised with unresolved peak separations, large sample volumes,
time-consuming derivatization, and long analysis times19,20. An
LC-MS/MS method, reported by Vemula et al. (2017), is the only
published method to separate eight isomeric aminobutyric acids
simultaneously21. However, their derivatization process and LC-MS
analysis was time and labor intensive and, more importantly, five
out of the eight aminobutyric acid isomers/enantiomers could not
be chromatographically separated. It was therefore important to
develop a fast, simple, and sensitive LC-MS method to chromato-
graphically separate and thus accurately quantify these isomeric
compounds in biological samples to more precisely determine their
pathphysiological roles.
We present a LC-MS/MS method that enables baseline
separation with sensitive detection of six underivatized amino-
butyric acid isomers (D,L-BAIBA, GABA, D,L-AABA, and
L-BABA) in minimal amounts of biological fluid samples (10 µL)
with a short LC-MS analysis (27 min), specifically for application
to the study of osteoporosis. We report specific signatures and
correlations between serum GABA or D-BAIBA levels and BMD
and physical activities in female cohorts of different ages, low or
high BMD values, and with or without osteoporotic fractures
(OF). The applicability of this method may lead to significant
advances in the detection and treatment of osteoporosis.
Results
Development and validation of LC-MS/MS method. For the
first time, to our knowledge, we successfully implemented a
methodology for complete separation of six isobaric aminobutyric
acids using liquid chromatography without derivatization
(Fig. 1a, Supplementary Table 1 and Supplementary Fig. 1). It was
then validated by determining a suitable surrogate matrix, cali-
bration linearity, limit of detection, accuracy, and precision. The
validation process followed the FDA’s Bioanalytical Method
Development Guidance for Industry22.
Linear regression lines were constructed for each biological
matrix versus 5% bovine serum albumin (BSA) in phosphate-
buffered saline (PBS, pH 7.4) at 11 concentrations, and linear
coefficient values were calculated as presented in Supplementary
Table 2. A slope of K= 1 from the linear equation implies
correlation and thus demonstrates similar matrix effects exerted
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by these two matrices23–26. As shown in Supplementary Table 2,
the slopes of the linear equations from four sets of solutions are
close to unity (0.87–1.12) for these analytes, indicating parallelism
of matrix effects presented between the surrogate matrix selected
and biological fluids. Comparison of chromatograms in 5% BSA-
PBS and various physical fluid samples in Fig. 1b–d also
demonstrated that no biological interference existed in BSA-
PBS for the detection of BAIBA, GABA, or AABA.
We conducted calibration curves for five aminobutyric acid
isomers of interest in the ranges of 0.02–20.48 µM for GABA,
L-BAIBA and D-BAIBA, and 0.16–163.84 µM for L-AABA and
D-AABA. The calibration ranges varied depending on the
sensitivity of the individual analyte and its expected endogenous
level in biological fluid samples. The calibration curves exhibited
excellent linearity (R2= 0.9992–0.9998) in the calibration ranges
established for all five aminobutyric acids (Table 1).
The limits of detection (LODs) were 0.01 µM for GABA,
L-BAIBA and D-BAIBA, and 0.08 µM for L-AABA and D-
AABA (Table 1). These LOD values correspond to the detection
limits of 10 pg and 80 pg, respectively, for the two groups of
aminobutyric acids. As shown at the lowest concentrations of
each calibration range in Table 1, the limit of quantification
(LOQs) were 0.02 µM for GABA, L-BAIBA and D-BAIBA, and
0.16 µM for L-AABA and D-AABA. As shown in Table 1, the
accuracies for all three levels of quality control (QC) samples
are in the range of 90.3–110.8% for all five aminobutyric
acid isomers analyzed. Relative standard deviation (RSD, an
indication of precision) for all three levels of QC samples were
in the range of 2.2–9.2%.
Quantification of aminobutyric acids in biological fluids. To
demonstrate the feasibility of the present LC–MS/MS method,
we measured aminobutyric acids in pooled plasma, serum and
cerebrospinal fluid (CSF) from healthy human subjects with
different ethnicity as well as from mice of different ages and sex.
The results summarized in Table 2 indicate that the predominant
type of BAIBA in humans is the R-enantiomer (D-BAIBA), with
concentrations of 0.34 ± 0.02 µM and 0.14 ± 0.01 µM in human
serum and CSF. In contrast, L-BAIBA was the primary isomeric
form in mouse (0.05 ± 0.01 µM). D-BAIBA was also detected in
the pooled healthy mouse serum, but the concentration was lower
than the LOQ and thus no quantification was obtained (Fig. 1b).
This finding with pooled human sera was further confirmed by
individual human serum samples. D-BAIBA serum levels were
remarkably higher than L-BAIBA in all six human serum samples
with various ethnicity, age, and gender (Table 2). The large
L-AABA peak at about 4.8 min was observed in all fluid samples
from both humans and mice, but D-AABA was not detected in
the samples (Fig. 1d). This suggests that L- is the only AABA
enantiomer naturally existing in biological fluids analyzed in the
present study.
Fig. 1 Chromatograms of each isomeric aminobutyric acid in different matrices. a Representative MS/MS chromatogram of isomeric aminobutyric acids
and deuterated standards in methanol. Peaks # labelled correspond to the compounds 1–11 in Supplementary Table 1. b–d Chromatograms of BAIBA (b),
GABA (c), and AABA (d) in surrogate matrix (5% BSA-PBS) and blank human serum, human CSF, mouse serum and mouse plasma.
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Applications of developed method in clinical studies. To
investigate the relationship between isomeric aminobutyric acids
and osteoporosis, serum samples from two clinical studies were
analyzed using the newly developed method: (1) 54 older women
(age: 48–80 years) with or without single or multiple fractures
(Supplementary Table 3); and (2) 136 younger women (age 21–41
years) with low or high BMD values (hip) (Supplementary
Table 4). In the older women group, the concentrations of three
quantified aminobutyric acids in non-osteoporotic (Control) vs.
osteoporotic (CASE) groups were 0.71–2.24 µM vs. 0.38–1.97 µM,
D-BAIBA, 0.09–0.20 µM vs. 0.08–0.16 µM, GABA, and
2.36–7.86 µM vs. 2.31–7.78 µM, L-AABA (Supplementary
Table 3). L-BAIBA was only detected in six of 136 younger
subjects and in none of 54 older female cohort. When we further
stratified these women based on the age: 48–59 years old and
60–80 years old, GABA levels were significanty lower in osteo-
porotic patients as compared with non-osteoporotic individuals
who are 60–80 years old (p= 0.040), but no difference for
those of 48–59 years old (p= 0.921) (Fig. 2a, b). A significant
positive correlation between serum D-BAIBA concentration and
T-score (hip) was obtained in the older women without any
fractures (Pearson’s 0.575, p= 0.0026, Fig. 2d). Intriguingly, this
correlation could not be found in women with fractures (Pear-
son’s −0.088, p= 0.67, Fig. 2e), despite a rigorous exclusion
criteria for those undergoing any treatment, perhaps pointing to
the complexity of fractures or potential effects of OF treatments.
Then we further compared serum aminobutyric acid isomer levels
with different number and locations of fractures. As compared
with the group with no fractures, serum D-BAIBA levels were
lower in the population with one or two osteoporotic fractures,
but at a similar level in the population with 3–4 fractures (Fig. 2f).
We did not detect significant differences for GABA and L-AABA
(Fig. 2g, h). Higher D-BAIBA levels can be found in serum from
patients with axial fractures, though this increased trend is not
statistically significant (p= 0.0516, Fig. 2i).
Results using serum from the 136 young women cohort
(Supplementary Table 4) showed that the levels of these isomers
were 0.58–6.20 µM (D-BAIBA), 0.21–0.74 µM (GABA), and
4.48–79.72 µM (L-AABA). L-BAIBA was only detected in the
serum samples from six subjects, with the average concentration
of 0.115 ± 0.030 µM (range of 0.076–0.157 µM). All these findings
revealed an increasing trend in the young or healthy conditions.
Given the highly significant positive association (Spearman’s 0.64,
p= 6.5 × 10−17) between hip BMDs and body mass index (BMI)
(Supplementary Fig. 2); and other BMI-correlated physical
parameters, including body weight and waist circumference in
this population, we performed additional analyses on the two
subgroups based on BMI: 82 lean women with normal BMI
(18.5–24.9 kg m−2), and 51 obese women with higher BMI
(≥25.0 kg m−2). Then the populations without osteoporosis/
osteopenia (T-score ≥−1) and with osteoporosis/osteopenia
(T-score <−1) were further grouped to identify metabolites
significantly associated with BMD/T-score. Spearman’s rank
correlation analysis was used to investigate the associations
between individual aminobutyric acid isomers and different
physical parameters including age, hip BMD/T-score, BMI,
current smoking, alcohol intake, physical activity, and dairy
consumption. We also performed partial Spearman’s rank
correlation analysis with all 136 samples as well as adjusting for
BMI and BMI-related covariates (p-value ≤ 0.05 in Spearman
correlation tests) to further investigate the pairwise associations
between three aminobutyric acids and each physical parameter
controlling for age, BMI, alcohol intake, and/or physical activity.
Results were summarized in Tables 3 and 4. Both D-BAIBA and
GABA exhibit a significant positive association with physical
activity in different populations, suggesting that exercise may
increase circulating serum concentrations. L-AABA significantly
associated with daily alcohol intake. To our knowledge, this result
is the first to link AABA with alcohol intake and is consistent
with previous findings linking elevated serum AABA to alcoholic
liver injury1,2. Even though no association was observed for D-
BAIBA with hip BMD in 85 young Caucasian women without
osteoporosis/osteopenia, it is interesting that, a positive correla-
tion (Spearman’s 0.37, p= 0.024) and a negative correlation
(Spearman’s −0.32, p= 0.029) were obtained in 38 lean and 47
obese individuals, respectively (Table 3). This suggests that D-
BAIBA associates to adiposity. GABA associated with bone mass
in all populations without osteoporosis/osteopenia (Table 3).
Genetic analyses for aminobutyric acid related genes. We
evaluated 12 genes coding for enzymes and receptors involed with
generation or signaling of the aminobutyric acids after analyzing
five different published meta-analysis (Supplementary Tables 5
Table 1 Validation results of limit of detection (LOD), calibration range, linearity, precision, and accuracy of the new assay.
Calibration curve Method Validation
LOD
(µM)
Linear range
(µM)
Linearity
(R2)
Prepared concentration
(µM)
Measured concentration
(µM)
Precision (CV %) Accuracy (%)
L-BAIBA 0.01 0.02–20.48 0.9998 0.32 0.33 ± 0.02 6.5 101.6
1.28 1.32 ± 0.08 5.8 103.5
5.12 5.22 ± 0.20 3.9 102.0
D-BAIBA 0.01 0.02–20.48 0.9992 0.32 0.29 ± 0.03 9.2 90.3
1.28 1.42 ± 0.07 5.2 110.8
5.12 5.45 ± 0.24 4.4 106.5
GABA 0.01 0.02–20.48 0.9999 0.16 0.17 ± 0.01 6.0 104.4
0.64 0.70 ± 0.03 3.8 109.1
2.56 2.58 ± 0.07 2.7 101.0
L-AABA 0.08 0.16–163.84 0.9994 2.56 2.38 ± 0.09 3.7 93.1
10.24 10.70 ± 0.26 2.5 104.5
40.96 42.28 ± 1.91 4.5 103.2
D-AABA 0.08 0.16–163.84 0.9995 2.56 2.52 ± 0.05 2.2 98.3
10.24 11.00 ± 0.37 3.4 107.5
40.96 41.35 ± 1.62 3.9 100.9
Eight-point calibration curves were prepared to the following concentrations: 0.02, 0.04, 0.08, 0.16, 0.64, 2.56, 10.24, and 20.48 µM for L-BAIBA and D-BAIBA; 0.02, 0.04, 0.08, 0.32, 1.28, 5.12, 10.24,
and 20.48 µM for GABA; 0.16, 0.32, 0.64, 1.28, 5.12, 20.48, 81.92, and 163.84 µM for L-AABA and D-AABA. Mean ± SD (n= 5) for method validation
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and 6). Three genes, G protein-coupled receptor 41 (FFAR3),
glycine receptor subunit alpha-2 (GLRA2), and glycine receptor
subunit alpha-4 (GLRA4), were excluded due to lack of genome-
wide association studies (GWAS) summary statistics. The results
of the gene-based analysis for MRGPRD and DPYD resulted
from bioinformatics analyses from other GWAS datasets.
Table 5 presents the results of the analyses of the genes
associated with the bone-related traits from five GWAS datasets.
We identified seven genes significantly associated with BMD-
related traits, among which three genes are essential for BAIBA
production and its effects, and the other four genes are needed for
GABA generation and effects.
The results of MRGPRD, a functional receptor for BAIBA,
from UK biobanks (UKBB) studies UKBB 2017, UKBB 2018, and
GEnetic Factors for OSteoporosis (GEFOS) Life Course datasets
demonstrated that the gene MRGPRD was associated with the
estimated BMD (eBMD) by quantitative heel ultrasounds (UKBB
2017: false discovery rate (FDR)= 0.0322, UKBB 2018:
FDR= 0.014) and total body BMD (GEFOS Life Course:
FDR= 0.027). In addition, UPB1, a gene encoding
β-ureidopropionase belonging to the CN hydrolase family was
found significantly associated with eBMD in the UKBB 2018
(FDR= 0.0272). In addition, we performed gene-based analyses
on both pooled cohorts and gender-specific cohorts from the
GEFOS2 study showing that UPB1 significantly associated with
femoral neck BMD (FN BMD) and lumbar spine BMD (LS BMD)
notably identified among the female cohorts.
Two functional receptors for GABA, GABBR2 (gamma-
aminobutyric acid type B receptor subunit 2), and GLRA1
(glycine receptor subunit alpha-1), and an essential enzyme for its
generation, GAD1 (glutamate decarboxylase), showed an associa-
tion with total body BMD among the pooled cohorts (Table 5). In
addition, GLRA1 was also significantly associated with total body
BMD among the group with age 60 years or over but not in the
younger groups. GABBR2, identified from the GEFOS ALLFX
study, is the only gene significantly related to fracture
(FDR= 0.0108) in the present analysis.
Correlation analysis for aminobutyric acid related genes. Since
osteoporosis is a metabolic syndrome, where inflammation plays a
major role, and given the relevance of peripheral blood monocytes
(PBM) to the pathogenesis of aging-related, inflammatory, and
degenerative diseases27–29, we investigated the gene expression
profiles for the aminobutyric acids-related genes from PBMs. PBM
information was available from 122 out of 136 young women
subjects with high or low BMD (Supplementary Table 7)30. The full
list of measured expression levels of seven aminobutyric acids-
related genes shown in Table 5 were summarized in Supplementary
Table 8. Expression profiles of aminobutyric acids-related genes that
only include DPYD, UPB1, and GABBR1, were used to investigate
the associations with aminobutyric acids and physical parameters.
Four genes, GABBR2, GAD1, GLRA1, and MRGPRD, were excluded
due to their extremely low expression (essentially absent) in per-
ipheral blood monocyte cells. We further investigated the four low-
expressed genes via ENCODE31 (https://www.encodeproject.org/)
and GTEx Portal32 (https://www.gtexportal.org/home/), and found
that GABBR2, GAD1, GLRA1, andMRGPRD were consistently low-
expressed in monocytes CD14+, osteoblasts, and whole blood cells
(Table 6 and Supplementary Fig. 3).
Among 122 subjects that have both transcriptomic and
metabolomics datasets, we used both Spearman’s and partial
Spearman’s correlation tests to explore the relationships of the
aminobutyric acid related genes with aminobutyric acids and
physical parameters, and results were summarized in Table 7.
Our results revealed a significant and positive associationT
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between two functional enzymes of D-BAIBA generation, DPYD
and UPB1 (p < 0.0001). Moreover, DPYD in peripheral blood
monocytes exhibited significantly positive association with both
physical activity (ρ′= 0.21, p= 0.0188) and hip BMD (ρ′= 0.17,
p= 0.0475) after controlling influences of physical parameters
such as age, BMI, alcohol intake, etc., while UPB1 level was found
to be positively associated with serum D-BAIBA level (ρ= 0.19,
p= 0.0361). Additionally, we found a significant correlation
between UPB1 and L-AABA (ρ′= 0.18, p= 0.0372) after
controlling age, BMI, etc, and this association has never been
reported before. The Spearman correlation test for a GABA
receptor coding gene GABBR1 in transcriptome profiling has
established a statistically significant negative correlation to both
physical activity (ρ=−0.17, p= 0.0499) and alcohol intake
(ρ=−0.22, p= 0.012).
Discussion
Osteoporosis is likely one of the most insidious chronic aging
condition, as it commonly goes unnoticed until a fragility fracture
occurs. Exercise increases both bone formation and muscle mass
associated with regulation of bone angiogenesis, and has been
recommended by the World Health Organization as a non-
pharmacologic prophylactic and treatment of osteoporosis33.
While we have gained a much greater understanding of both
osteoporosis and exercise effects at the organismal level, the full
cellular-molecular-metabolic machinery is yet unknown. Because
of the recent enhanced awareness for the roles of aminobutyric
acids in health and disease, their metabolic roles, and their
potential involvement with musculoskeletal pathophysiology and
exercise, it is essential to quantify precisely these molecules
to investigate their specific roles and intracellular signaling
mechanisms.
However, as these isomeric analytes are small and polar, they
quickly elute out of the column at the void volume, making it
difficult to quantify them with baseline seperation under reversed
phase HPLC conditions. Previous studies by Rea et al. have
demonstrated that a number of co-eluted peaks of biological origin
compromised the accurate detection of GABA even with pre-
derivatization and an extended retention time of more than
60min34. Incomplete separation of GABA could lead to high basal
values of GABA and interactions with unknown compounds that
Fig. 2 Measurement of serum isomeric aminobutyric acid levels in the older women group (48–80 years old) without osteoporotic fractures (Control)
or with osteoporotic fractures (CASE). a–c Comparison of serum levels of isomeric aminobutyric acids, D-BAIBA (a), GABA (b), and L-AABA (c), in
women with (CASE) or without osteoporotic fractures (Control) at different age. Mean ± SD, n= 13 pairs in the age of 48–59 years group, and n= 14 pairs
in the age of 60–80 years group. d, e Correlations between serum D-BAIBA levels and T-score (THIP) from women (48–80 years old), in the group of no
osteoporotic fractures (d) and osteoporotic fractures (e). n= 27 for each group. f–h Serum levels of aminobutyric acid isomers, f D-BAIBA, g GABA, and
h L-AABA, in women with different number of osteoporotic fracture locations. Mean ± SD, n= 27 for 0 fracture locations, n= 8 for 1 fracture location,
n= 10 for 2 fracture locations, and n= 9 for 3–4 fracture locations. i Comparison of serum levels of isomeric aminobutyric acids in patients with
appendicular fractures vs. axial fractures. Mean ± SD, n= 9 for axial fractures, and n= 18 for appendicular fractures.
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mask the true pharmacological efficacy of GABA34. In this study,
our method achieved baseline separation for these six isomers
using our newly developed LC-MS/MS method (Fig. 1a). In
addition, to our knowledge, this is the first report of complete,
simultaneous separation of these isomers/enantiomers by
liquid chromatography, without the time-consuming derivatiza-
tion process, thereby enhancing sensitivity and efficiency of
sample analysis and insuring accurate measurement of each single
isomer.
Previous studies have reported reduced serum BAIBA levels of
0.21–0.61 µM in patients with significantly reduced physical
activity such as those on hemodialysis13. Animal research sug-
gested that BAIBA levels were about 0.6–2 µM in mouse plasma15.
The normal concentration range for AABA has been reported to
be less than 41 μM in human plasma35, but the concentration
could increase up to 151 μM under pathological conditions35.
Even though these studies did not quantitate separate enantio-
mers, the LOQ values and linear range of the calibration curves for
both R(D) and S(L) enantiomers of BAIBA or AABA in the pre-
sent LC-MS/MS method seem in excellent agreement with the
total levels in control and disease serum. Similarly, the plasma/
serum GABA levels in the healthy human subjects typically vary
from 0.2 to 1.0 µM36–38, but under neurological disorders, GABA
concentrations decrease to 65–275 nM in CSF and 179–498 nM in
plasma39. Thus, our method could be suitable for monitoring and
screening GABA levels from differential biological samples under
healthy or pathological conditions.
To demonstrate the clinical applications of the new metho-
dology, we quantified aminobutyric acid isomers in serum sam-
ples from human female populations with and without
osteoporosis. In the older women population, significantly lower
levels of GABA in the OF group for the subjects of 60–80 years
old demonstrated a highly significant association between GABA
and bone function during aging (Fig. 2b). Previous studies
showed that GABA can stimulate osteoblastogenesis via the
activation of GABA B receptor, which is predominantly expressed
by osteoblasts40,41, to favor bone formation. Additionally, GABA
may also mitigate osteoporosis by inhibiting the activity of
inflammatory cytokines and suppressing oxidative stress-induced
cell death41. Our findings provide further evidence supporting
that GABA might be necessary for optimal bone function parti-
cularly in the elderly population (Fig. 3).
A positive correlation between T-score (hip) and D-BAIBA
levels was confirmed in the population without OF, suggesting
that the individuals with lower BMD have relatively lower D-
BAIBA concentrations in serum (Fig. 2d). This finding may
provide an explanation for results in Fig. 2a, i.e., serum D-BAIBA
levels might decrease during the development of osteoporosis in
normal individuals. Interestingly, no similar association was
found in the osteoporotic group (Fig. 2e). This discrepancy could
Table 3 Association analysis of serum isomeric aminobutyric acids with physical parameters in young Caucasian women (age
21–41 years) using Spearman correlation test.
Populations Correlations between various serum isomeric aminobutyric acids and physical parameters
BMI T-score Physical
parameters
Aminobutyric Acids Precursors Sample size ρ p-value
All All Physical activity GABA Glutamine 136 0.28 0.0012
Alcohol intake D-BAIBA Thymine 136 0.19 0.032
L-AABA Methionine,
threonine
136 0.25 0.0029
≥−1 (No osteopenia
or osteoporosis)
BMD GABA Glutamine 85 −0.25 0.021
Physical activity GABA Glutamine 85 0.34 0.0016
D-BAIBA Thymine 85 0.24 0.026
<−1 (osteoporosis) Alcohol intake L-AABA Methionine,
threonine
51 0.38 0.006
18.5–24.9 kg m−2 (Lean) All Physical activity GABA Glutamine 82 0.31 0.0055
Alcohol intake L-AABA Methionine,
threonine
82 0.22 0.047
≥−1 (No osteopenia
or osteoporosis)
BMD D-BAIBA Thymine 38 0.37 0.024
Physical activity GABA Glutamine 38 0.39 0.018
D-BAIBA Thymine 38 0.33 0.044
<−1 (osteoporosis) Alcohol intake L-AABA Methionine,
threonine
44 0.38 0.012
≥25.0 kgm−2 (Overweight,
obese, extremely obese)
All Alcohol intake L-AABA Methionine,
threonine
51 0.41 0.0029
≥−1 (No osteopenia
or osteoporosis)
BMD D-BAIBA Thymine 47 −0.32 0.029
Alcohol intake L-AABA Methionine,
threonine
47 0.40 0.0053
ρ Spearman’s ranked correlation coefficient
Table 4 Summary of association analysis of serum isomeric aminobutyric acids with physical parameters in young Caucasian
women (age 21–41 years) using partial Spearman correlation test.
Correlation Sample size ρ‘ 95% lower bound 95% upper bound p-value Control
L-AABA vs. alcohol intake 136 0.27 0.1 0.42 0.0021 Age, BMI, physical activity
D-BAIBA vs. physical activity 136 0.25 0.08 0.41 0.0041 Age, BMI, alcohol intake
ρ‘ partial Spearman’s ranked correlation coefficient
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be due to surgical and/or medical treatments after fracture
occurance, particularly for those patients with multiple fractures.
Such treatments might help stabilize or increase bone formation,
leading to some restoration of BAIBA levels.
An intriguing finding was that we only detected L-BAIBA in
six subjects out of the 190 human subjects studied whereas in
mice L and not D-BAIBA is the major enantiomer in serum. We
demonstrated in mice that L-BAIBA and not D-BAIBA is pro-
duced by contracted muscle18 and it has been shown that total
BAIBA levels are elevated after exercise15. Therefore, it will be
important to perform time course studies using subjects subjected
to different forms of exercise to determine if L-BAIBA is also
elevated in humans in response to exercise.
It has been reported that peak BMD achieved and maintained
in individuals aged 20–40 years is the most powerful predictor of
post-menopausal osteoporosis42. One of our major goals of
focusing these studies on a younger group of women is to attempt
to identify biomarkers for early detection of osteopenia/osteo-
porosis. A positive correlation (p= 0.024) was obtained between
D-BAIBA and BMD in the women with normal BMI, (Table 2)
and this result is consistent with what we found in the older
women without osteoporotic fractures: higher serum D-BAIBA is
linked with higher bone density. A recent study using MC3T3-E1
cells has reported that BAIBA can dramatically stimulate pro-
liferation and differentiation of osteoblasts via activating ROS
signaling pathways, inducing bone formation43. Interestingly,
D-BAIBA was found to be inversely associated with BMD
(p= 0.029) in the populations of overweight, obese, or extremely
obese in our study. Gerszten’s group has reported that plasma
concentration of total BAIBA is negatively associated with
metabolic risk factors such as triglycerides, total cholesterol, BMI,
etc.15, suggesting a lower BAIBA level in the obese as compared
with lean populations. Moreover, a significant elevation of serum
levels of various hormones, cytokines, conventional metabolites,
amino acids, and fatty acids occurs in obese compared to lean
subjects44. All these findings might provide insights for potential
apparent discrepancies in observed associations between
D-BAIBA vs BMD when specific populations present with dif-
ferent metabolic profiles, and further supports its use as a new
biomarker for many of these conditions.
To further our understanding of these important associations
between BAIBA/GABA and BMD and fractures, we resorted to
Table 6 Expression levels of aminobutyric acid related genes.
Gene Ensembl ID Measured expression Reference expression
Peripheral blood
monocytes
Peripheral blood
monocytes
RNA-seq (ENCODE) GTEx
Monocytes CD14+ Osteoblasts Whole blood
(Average TPM) (Median TPM) (Average RPKM) (Average RPKM) (Median TPM)
DPYD ENSG00000188641 155.9 170.7 6.7 4 20.1
MRGPRD ENSG00000172938 0 0 0 0 0
UPB1 ENSG00000100024 0.3 0.2 0 0 1.2
GABBR1 ENSG00000204681 39.4 31 23.6 0.2 19.6
GABBR2 ENSG00000136928 0 0 0 0 0
GAD1 ENSG00000128683 0 0 0 0 0
GLRA1 ENSG00000145888 0 0 0 0 0
the reference expression profiles for other cells/tissue were obtained from ENCODE (https://www.encodeproject.org/) and GTEx Portal (https://www.gtexportal.org/home/) on October 30, 2019
TPM transcripts per million, RPKM reads per kilobase million
Table 5 Summary of VEGAS gene-based association results (FDR < 0.05).
Aminobutyric acids Genes Traits p-value FDR Best SNP SNP p-value
BAIBA DPYD Total body BMDa 0.011 0.049 rs9701777 0.00052
MRGPRD Total body BMDa 0.0067 0.049 rs143309852 0.014
eBMDb 0.0040 0.032 rs34847539 0.00029
eBMDc 0.0017 0.014 rs34847539 0.000049
UPB1 eBMDc 0.0068 0.027 rs5760459 0.00070
FN BMDd (Female
cohort only)
0.00030 0.0015 rs2070474 0.00032
LS BMDd (Female cohort only) 0.0026 0.021 rs6004171 0.00080
GABA GABBR1 eBMDc 0.000022 0.00011 rs73404750 3.5 × 10−12
GABBR2 Fracturee 0.0022 0.011 rs11789969 0.00017
Total body BMDa 0.028 0.047 rs35126377 0.00054
GAD1 Total body BMDa 0.023 0.047 rs150390985 0.00074
GLRA1 Total body BMDa 0.0043 0.022 rs56177246 0.0058
Total body BMDa (Age≥
60 years)
0.0090 0.045 rs145077031 0.0011
The p-value was calculated by using the VEGAS gene-based association genes coding for enzymes and receptors directly associated with BAIBA and GABA metabolism. False discovery rates with
Benjamini-Hochberg multiple test correction was calculated for the adjusted p-values and denoted by FDR. Best SNP and SNP p-value represent the most significant SNPs within the genes associated
with BAIBA and GABA metabolism and the corresponding SNP p-value, respectively
BMD bone mineral density, eBMD bone mineral density estimated from quantitative heel ultrasounds, FB BMD femoral neck BMD, LS-BMD lumbar spine BMD
aGEFOS Life Course
bUKBB 2017
cUKBB 2018
dGEFOS2
eGEFOS ALLFX
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bioinformatics analyses based on five powerful GWAS studies of
specific genes associated with BMD-related traits. Strikingly,
seven of the 12 genes related to BAIBA/GABA showed significant
single nucleotide polymorphisms (SNPs) that are associated with
BMD and/or fractures, and all these seven genes are essential for
the proper metabolism and effects of BAIBA and GABA. These
findings point to the potential genetic modifiers of aminobutyric
acids generation/metabolism. Activity/exercise is a major mod-
ulator of BAIBA, and we now propose that GABA by controlling
muscle tonicity could also exert modulatory effects on levels of
BAIBA and its effects (Fig. 3). Our bioinformatics discovered that
the SNPs in a key enzyme, UPB1, and a major signaling receptor,
MRGPRD, directly involved with availabilty and effects of BAIBA
are associated with BMD. This finding is further strongly sup-
ported by our transcriptomics analysis of RNA-seq data in per-
ipheral monocytes isolated from the 122 young women cohort.
The expression level of the gene UPB1 in peripheral blood
monocytes is positively associated with serum D-BAIBA level and
the gene DPYD, encoding an enzyme necessary for D-BAIBA
generation, exhibits significantly positive association with both
physical activity and hip BMD (Table 7). All these results provide
strong rationale or support for the positive association observed
between D-BAIBA serum levels and hip T-scores in healthy
women. This study also suggests for the first time that peripheral
blood monocytes may have the capacity to generate D-BAIBA, to
our knowledge.
Furthermore, we discovered that two genes coding for the
GABA receptors GABBR2 and GLRA1 and the gene coding for
glutamate decarboxylase GAD1, showed an association with total
body BMD, and remarkably GABBR2 associated with bone
fractures. GABBR2 belongs to the G-protein-coupled receptor
family C and GABA-B receptor subfamily45. The GABA-B
receptors inhibit neuronal activity by regulating the release of
neurotransmitters, and the activity of ion channels and adenylyl
cyclase46. Known diseases associated with this gene include
neurodevelopmental disorders47. GAD1 codes for the enzyme
responsible for catalyzing the production of gamma-aminobutyric
acid from L-glutamic acid, and is associated with diseases such as
cerebral palsy, spastic quadriplegic, and inherited congenital
spastic tetraplegia48,49. It may also play a role in stiff-person
syndrome50. GLRA1 codes for a subunit of the pentameric
inhibitory glycine receptor. Diseases associated with GLRA1
include hyperekplexia, which induce severe stiffness51. Another
G-protein-coupled receptor family C group 6 subtype A
(GPRC6A), though not directly related to BAIBA and GABA, is
very important for bone and muscle function as it is activated by
amino acids with a preference for the basic and small amino acids
such as L-Lys, L-Arg and L-ornithine, and is also directly acti-
vated by extracellular calcium and osteocalcin52,53. Recently,
multiple physiological abnormalities including a disruption in
bone metabolism have been reported in GPRC6A(−/−) mice54,
and its function in osteoblasts was further reported in humans55.
These data point to the much broader role of GABA on basic
skeletal muscle tone, which influences overall musculoskeletal
function and body metabolism. In light of current new concepts
on bone-muscle biochemical crosstalk, exploring the functions of
BAIBA and GABA as molecules mediating such crosstalk could
prove to be very important for the exploration of new therapeutic
interventions for musculoskeletal diseases. It is tantalizing to
propose that basic skeletal muscle tonus could be way more
important as a basic signaling mechanisms than we previously
envisioned (Fig. 3).
Exercise increases the release of myokines such as BAIBA, but
the exact mechanisms of the beneficial effects of exercise on
musculoskeletal health are far from being fully understood. Pre-
vious studies have reported elevated BAIBA in plasma afterT
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exercise training intervention in both human and mice studies15,
exercise also increases GABA levels in brain56, gastrocnemius and
quadriceps7, and systemic circulation7. Exercise stimulates the
generation of these active compounds from muscle, which can
further modulate browning of white fat and insulin resistance15,
regulate osteoblastogenesis and osteoclastogenesis40, prevent loss
of bone mass and muscle function9,18, suppress production of
proinflammatory cytokines57, and play an important role on bone
health58. In our study, the circulating concentrations of two
isomeric aminobutyric acids, D-BAIBA and GABA, showed
positive associations with physical activity in population of 136
young to middle-aged female individuals with low or high hip
BMDs, lean mass, but no association in obese women (Table 2).
This suggests a differential metabolomic profile of D-BAIBA and
GABA in muscle and adipose tissues, or a significantly differential
influence of fatty acid metabolism on generation or metabolism of
D-BAIBA/GABA.
In summary, one of the major challenges in understanding the
physiological and pathophysiological roles of isomeric aminobu-
tyric acids is to successfully separate these highly biologically
active compounds. Currently, most of the available epidemiolo-
gical and experimental studies cannot distinguish between iso-
mers/enantiomers of those compounds, particularly L-BAIBA
and D-BAIBA, and therefore have most likely led to misleading or
uninterpretable results. To the best of our knowledge, our work is
the first to report the complete separation of these isobaric
compounds in liquid chromatography without derivatization.
This method offers a quick screening with high sensitivity and
accuracy for biomarkers of diseases in the plasma, serum, CSF, or
other biological fluid samples from patients, and would sig-
nificantly benefit and promote the future research associated with
these specific isomer/enantiomers in basic research and clinical
settings. This newly developed method has now been successfully
applied to osteoporosis clinical research studies, and has revealed
specific signatures and correlations in women with low and high
BMD and in women with one or more OF. In addition, our
systematic bioinformatics studies showed that specific SNPs in
BAIBA and GABA receptors important for their metabolism and
actions are associated with BMD and fractures. These studies
open new possibilities for the utilization of aminobutyric acids for
the potential diagnosis and prognosis of osteoporosis, and likely a
host of musculoskeletal diseases.
Methods
Chemicals and reagents. Pooled healthy human sera and mouse serum were
purchased from Sigma–Aldrich (St. Louis, MO). CD1 mouse plasma K2 EDTA was
obtained from Innovative Research Inc. (Novi, MI). Pooled normal human cere-
brospinal fluid was purchased from Fisher Scientific (Pittsburgh, PA). Human
serum from donors with different backgrounds of ethnicity, gender, and age were
purchased from Zen-Bio, Inc. (Research Triangle Park, NC). (S)-3-aminoisobutyric
acid (L-BAIBA) and (R)-3-aminoisobutyric acid (D-BAIBA) were purchased from
Adipogen Corp. (San Diego, CA), (S)-2-aminobutyric acid (L-AABA) and (R)-2-
aminobutyric acid (D-AABA) were purchased from Thermo Fisher Scientific
(Waltham, MA), 4-aminobutyric acid (GABA), (S)-3-aminobutyric acid (L-BABA),
and 4-aminobutyric-d6 acid (GABA-d6) were purchased from Sigma–Aldrich
(St. Louis, MO). DL-2-aminobutyric-2,3,3,4,4,4-d6 acid (D,L-AABA-d6) and (±)-3-
amino-iso-butyric-2,3,3-d3 acid (D,L-BAIBA-d3) were obtained from CDN Isotopes
(Pointe-Claire, Quebec, Canada). Monocyte Isolation Kit II was purchased from
Miltenyi Biotec Gmbh (Bergisch Gladbach, Germany). AllPrep RNA Universal Kit
was purchased from Qiagen (Germantown, MD). KAPA RNA Hyper kit with
RiboErase was obtained from KAPA Biosystems (Wilmington, MA). Qubit ds DNA
Fig. 3 Generation and signaling pathways of GABA and BAIBA in bone-muscle crosstalk. MRGPRD, MAS-related GPR family member D; FFAR3,
G-protein-coupled receptor 41; GABAaR, gamma-aminobutyric acid type A receptor; GABBR1-2, gamma-aminobutyric acid type B receptor subunit 1–2;
GLRA1-4, glycine receptor alpha 1–4; GAD, glutamate decarboxylase. GABA is generated in CNS, spinal cord, and though its central and peripheral action
controls muscle tonicity. BAIBA is a myokine secreted from skeletal muscles with known direct effects in bone/osteocytes in mice. Exercise increases the
secretion of both myokines and osteokines that can have autocrine and paracrine effects. GABA is a major neurotransmitter controling muscle tonicity.
The dotted lines with question marks are hypothetical concepts that muscle tonicty might influence the level of release of myokines, which in turn can
influence the levels of BAIBA, while BAIBA might further modulate tonicity.The receptors for GABA and BAIBA mediate their functions and potential SNPs
we report might act as modifiers of these effects. Therefore, we postulate that muscle tonicity could be a new mechanism for the fine-tuning of myokines
release and its effects on bone and muscle.
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HS Assay kit was purchased from Life Technologies (Carlsbad, CA). Formic acid
(reagent grade, ≥95%), ammonium formate, bovine serum albumin, Histopaque-
1077, and ethylenediaminetetraacetic acid (EDTA) were obtained from
Sigma–Aldrich (St. Louis, MO). PBS was purchased from Fisher Scientific (Pitts-
burgh, PA). HPLC-MS grade acetonitrile, water, and methanol were purchased from
J.T. Baker (Phillipsburg, NJ).
LC-MS/MS conditions. The LC system was equipped with pumps A and B (LC-
30AD), and autosampler (SIL-30AC) (Shimadzu Scientific Instruments, Inc.,
Tokyo, Japan). The LC separation was conducted on a chiral SPP-TeicoShell, 150 ×
4.6 mm, 2.7 µm column (AZYP LLC., Arlington, TX) configured with a Max-RP
50 × 2.0 mm as guard column (Phenomenex, Torrance, CA). The analytical column
was maintained at room temperature. The mobile-phase consists of methanol (A)
and buffer (B). The buffer is containing 0.005% formic acid and 2.5 mM ammo-
nium formate in water. The LC gradient program was: 0.0–10 min, 25% B;
10–10.1 min, 25–98% B; 10.1–17.0 min, 98% B; 17.1–25 min, 25% B. The flow rate
was 0.6 mLmin−1.
The LC-MS/MS analysis was performed on a Shimadzu LCMS-8050 triple
quadrupole mass spectrometer. The instrument was operated and optimized under
positive electrospray and multiple reaction monitoring modes (+ESI MRM) using
pure standard solutions. The optimized conditions are as follows: interface voltage,
4.0 kV; interface temperature, 300 °C; DL temperature, 300 °C; heating block
temperature, 400 °C; drying gas (N2), 10 L min−1; nebulizing gas (N2), 3 L min−1;
heating gas (Air), 10 L min−1; CID gas (Ar), 230 kPa. The m/z transitions
(precursor to product ions) and their tuning voltages were selected based on the
best MRM responses from instrumental method optimization software and were
presented in Supplementary Table 1. All analyses and data processing were
completed on Shimadzu LabSolutions V5.91 software.
The protonated molecular ion (m/z 104+, M+H) for all aminobutyric acid
isomers produced similar CID fragment ions: m/z 86+ ([M+H-H2O]+), m/z 87+
([M+H-NH3]+), m/z 69+ ([M+H-H2O-NH3]+), and m/z 58+ ([M+H-
HCOOH]+). The m/z transitions that can be used for quantification are m/z
104+ → 86+, m/z 104+ → 87+, m/z 104+ → 69+, and m/z 104+ → 58+. The
MRM mass transitions used (Supplementary Table 1) in this method were m/z
104+ → 58+ for L- and D-AABA, and m/z 104+→86+ or 69+ for the other four
isomers based on the optimization results obtained using the Shimadzu automatic
method optimization software. After a series of mobile-phase optimization steps
with different combinations of organic and aqueous compositions (water,
methanol, and acetonitrile) in various amounts of different additives (formic acid,
acetic acid, trifluoroacetic acid, ammonium formate, and ammonium acetate),
baseline resolution of these six isomers was achieved (Fig. 1a) without a time-
consuming derivatization process. The mobile-phase composition consists of (A)
methanol and (B) 0.005% formic acid and 2.5 mM ammonium formate in water.
Sample preparation for evaluation of matrix effect. Matrix effect is defined as
the effect of co-eluting residual matrix components on the ionization of the target
analyte, thus matrix can have a significant influence on the accuracy, precision, and
robustness of bioanalytical methods, particularly for LC-electrospray ionization
(ESI)-MS/MS methods24. BSA dissolved in PBS has been widely used in the past to
mimic plasma/serum in bioanalysis59, and was considered the best choice among
other methods as it contains the most similar chemical background to most bio-
logical fluids60,61. In this study, we selected 5% BSA-PBS as a surrogate matrix to
establish the standard calibration curves and validate the method. The following
parallelism tests were performed to verify the similarity of matrix effects exerted by
5% BSA-PBS and the four kinds of biological fluids including human serum,
human CSF, mouse serum and mouse plasma.
Stock solutions of each standard and internal standard (IS) were prepared
individually at the concentration of 0.2 M in water. Five isomeric aminobutyric
acid standards (L-BAIBA, D-BAIBA, GABA, L-AABA, and D-AABA) of interest
and their corresponding deuterated compounds (Supplementary Table 1) were
spiked in surrogate matrix 5% BSA-PBS (5% BSA in PBS, pH 7.4, w/v) as well as
human serum, human CSF, mouse serum, and mouse plasma. Eleven
concentration-level solutions were prepared by diluting the stock solution with
corresponding matrices: 0.02, 0.04, 0.08, 0.16, 0.32, 0.64, 1.28, 2.56, 5.12, 10.24, and
20.48 µM for GABA, L-BAIBA and D-BAIBA; 0.16, 0.32, 0.64, 1.28, 2.56, 5.12,
10.24, 20.48, 40.96, 81.92, and 163.84 µM for L-AABA and D-AABA. IS mixture
solution (D,L-BAIBA-d3, D,L-AABA-d6, and GABA-d6) was prepared at the
concentration of 1.2 µM by dilution of stock solution in methanol containing 0.1%
formic acid (v/v). Ten microliters of each sample was mixed with 10 μL IS solution
and 35 µL 0.1% formic acid in methanol (v/v). The mixtures were shaken for
20 min at room temperature, and then centrifuged at 12,000 × g, 4 °C for 15 min to
precipitate the proteins. The supernatant was transferred to an autosampler vial
and 45 µL of each sample was directly injected for LC-MS/MS analysis. Then
parallelism of matrix effects was assessed by plotting the concentration-dependent
response ratios (standard response normalized by respective IS response) from
biological samples to those from 5% BSA-PBS surrogate matrix.
Preparation of standard calibration curves and QC samples. As the above
evaluations demonstrated that the matrix effects between 5% BSA-PBS and other
four types of samples studied were very similar, the analyte-free 5% BSA-PBS can
be used as an ideal surrogate matrix. All samples in the following tests were
prepared in 5% BSA-PBS to establish standard calibration curves and validate the
method.
The samples of standard calibration curves and QC were prepared by spiking
the pure standards in surrogate matrix (5% BSA-PBS). The samples for eight-point
calibration curves were prepared by diluting the working solution to the following
concentrations: 0.02, 0.04, 0.08, 0.16, 0.64, 2.56, 10.24, and 20.48 µM for L-BAIBA
and D-BAIBA; 0.02, 0.04, 0.08, 0.32, 1.28, 5.12, 10.24, and 20.48 µM for GABA;
0.16, 0.32, 0.64, 1.28, 5.12, 20.48, 81.92, and 163.84 µM for L-AABA and D-AABA.
QC samples were similarly prepared in quintuplicate at 0.32, 1.28, and 5.12 µM for
L-BAIBA and D-BAIBA; 0.16, 0.64, and 2.56 µM for GABA; and 2.56, 10.24, and
40.96 µM for L-AABA and D-AABA. Ten microliters of each sample was mixed
with 10 μL IS mixture solution (1.2 µM, in 0.1% formic acid in methanol, v/v) and
35 µL of 0.1% formic acid in methanol (v/v). Then the mixtures were shaken for
20 min at room temperature, followed by the centrifugation at 12,000 × g, 4 °C for
15 min to precipitate protein. Finally, 45 μL of supernatant from each sample was
injected for LC-MS/MS analysis.
The limits of detection and quantification (LODs and LOQs, respectively) were
determined as the lowest concentration of each analyte detected with a signal-to-
noise ratio of 3 and 10, respectively62,63, and <15% of relative standard deviation
(RSD) in five replicates.
The accuracy and precision of the method were determined by analyzing the
QC samples in quintuplicate at three concentration levels: 0.32, 1.28, and 5.12 µM
for L-BAIBA and D-BAIBA; 0.16, 0.64, and 2.56 µM for GABA; and 2.56, 10.24,
and 40.96 µM for L-AABA and D-AABA.
Preparation of biological fluid samples. Ten microliter biological fluid samples
and same volume of IS mixture solution (1.2 µM, 0.1% formic acid in methanol,
v/v) were added to 35 µL of 0.1% formic acid in methanol (v/v), followed by
20 min-shaking at room temperature and another 15 min-centrifugation at
12,000 × g, 4 °C to precipitate protein. The supernatant was directly transferred to
an autosampler vial and 45 μL of each sample was injected for LC-MS/MS analysis.
Peripheral blood monocytes (PBM) isolation. The human peripheral blood
samples were collected from ongoing projects of the Louisiana Osteoporosis Study.
First, peripheral blood mononuclear cells (PBMCs) were obtained from 60 milliliter
human peripheral blood by density gradient centrifugation on Histopaque-1077.
The PBMCs were washed with phosphate-buffered saline (PBS) and then used for
PBM isolation with the Monocyte Isolation Kit II according to the manufacture’s
instructions. The isolated PBMs were examined for purity and counted under
microscope using a hemocytometer. The total RNA used for RNA-seq were
extracted from the freshly isolated PBMs with the AllPrep RNA Universal Kit and
kept at −80 °C for further use.
Transcriptomics analysis of RNA-seq data. RNA-seq libraries were constructed
from 500 ng RNA of each sample using KAPA RNA Hyper kit with RiboErase
following the manufacturer’s instructions. Different adaptors were used for mul-
tiplexing samples in one sequencing run. Library concentrations and quality were
examined by Qubit ds DNA HS Assay kit and Agilent 4150 Tapestation system
(Agilent, Santa Clara, CA). The libraries were pooled and diluted to 2 nM in elution
buffer (10 mM Tris-HCL, pH 8.5) and then denatured using the Illumina protocol.
The denatured libraries were diluted to 10 pM by pre-chilled hybridization buffer
and loaded onto Illumina NextSeq 500 (Illumina, San Diego, CA) and run for 75
cycles using a single-read recipe according to the manufacturer’s instructions. The
data quality examination and demultiplexing procedure were implemented with
Illumina SAV and Illumina Bcl2fastq2 version 2.17 program, respectively. TopHat
(version 2.0.13)64 was applied to align sequencing reads to the human reference
genome assembly GRCh37 (hg19) for unique alignments. RefSeq transcript
annotations were obtained from the UCSC Genome Browser65, and read fragments
aligned to known exons were counted per gene using Htseq (version 0.6.1p1)66. All
analyses were conducted at the gene level. The RNA-seq raw counts were nor-
malized to the transcripts per million (TPM) unit for the following analyses.
Recruitment of human subjects. For the older women group containing both
fracturing women and controls, Creighton University Osteoporosis Research
Center (ORC) recruited the 54 subjects. The detailed characteristics of the study
subjects are shown in Supplementary Table 3. The investigators queried ORC
database of persons who had been patients or subjects in previous studies and had
consented to be contacted for future studies. ORC purchased lists of primary care
physicians and nurse practitioners and sent letters asking them to refer patients.
ORC also posted advertisement on the ORC website and their Facebook page.
Moreover, ORC contacted orthopedic surgeons to assist in identifying fracturing
patients who might qualify for the study. In this cohort, the International Physical
Activity Questionnaire was used to quantify physical activity. All of the vertebral
fractures were picked up on X-ray; none were acute. Additionally, the following
were exclusionary: (1) treatment with Forteo (ever); (2) treatment with Bispho-
sphonates: Fosamax, Actonel, Boniva, and Reclast. Exception was made if the
treatment was more than 10 years prior or only one dose; (3) treatment with bone
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active agents within the previous 6 months: Calcitonin, Estrogen, SERM, Depo-
Provera, Denosumab, Evista; (4) systemic corticosteroid for more than 6 months
duration or any corticoid therapy within the previous 6 months; (5) anticonvulsant
therapy within the previous year; and (6) anyone with surgical fixation (metal).
A total of 136 Caucasian females with age between 21–41 years old were
recruited from participants in the Louisiana Osteoporosis Study (LOS), a cross-
sectional study with ongoing recruitment to build a large sample pool
(~20,000 subjects) and database for research studies of osteoporosis and other
musculoskeletal diseases/traits67,68. The 136 subjects included 65 young women
with relatively high BMD and 71 young women with relatively low BMD,
corresponding to hip BMD Z scores ≥0.8 and ≤−0.8, respectively. Hip BMD was
determined as the combined BMD of the femoral neck, trochanter, and
intertrochanteric region measured by Hologic Discovery-A DXA (dual energy X-
ray absorptiometry) machine. The DXA machine was calibrated daily, and the
coefficient of variation (CV) value of the DXA measurements at total hip on
Hologic Discovery-A was 1.0%. For each study subject, weight, height, waist
circumference were measured using standard procedures. Lifestyle factors (e.g.,
exercise, alcohol consumption, smoking, total dairy consumption, etc.) and medical
history were assessed by questionnaires. For example, the participant had to first
answer whether they performed any physical activity (with a binary answer: yes/
no). If the participant answered yes to that question, then the follow-up question
asked for the number of days they engaged in physical activity per week. A set of
stringent exclusion criteria69 were adopted to minimize potential confounding
effects of non-genetic influence (by physiological and pharmacological conditions)
on BMD variation. The detailed characteristics of the study subjects are shown in
Supplementary Table 4. Total 122 out of these 136 subjects were involved in
transcriptomics analysis (RNA-seq) for their PBMs. Detailed characteristics of
these 122 subjects are shown in Supplementary Table 7.
GWAS analysis for aminobutyric acids-related genes. We analyzed five dif-
ferent published meta-analysis on genome-wide association studies (GWAS) on
BMD of various skeletal sites and fracture traits. The data were downloaded from
the GEnetic Factors for OSteoporosis (GEFOS) consortium (http://www.gefos.org/).
BMD in these studies is determined by DXA in GEFOS2 and GEFOS Life course
studies, whereas the UK biobanks (UKBB) studies (i.e., UKBB2017 and UKBB2018)
estimated the BMD by quantitative heel ultrasounds (eBMD). Fracture traits were
provided in GEFOS2 ALLFX and the UKBB studies and identified by hospital-based
fracture diagnosis (i.e., ICD10 codes) or a self-reported fracture based on ques-
tionnaire. Subjects reported any fracture that happened within the past 5 years.
Subjects were excluded if they had suffered fracture of the skull, face, hands, and feet
or they presented with pathological fractures due to malignancy, atypical femoral
fractures, periprosthetic, or healed fracture codes. Supplementary Table 5 is a
summary of the GWAS datasets.
In order to evaluate the association of the gene coding for the enzymes and
receptors of aminobutyric acids with BMD and fractures, Versatile Gene-based
Association Study −2 version 2 (VEGAS2) was implemented. This method is
commonly used for GWAS and analysis of summary statistics70. The fundamental
statistical estimation of VEGAS2 takes into account the linkage disequilibrium
(LD) of SNPs within a gene and performs permutation-based simulation to obtain
gene-based p-values. We used the association signal from all the SNPs within the
region of each gene. The false discovery rate (FDR) was used to address multiple
comparisons issue and the adjusted p-values was obtained for the enzymes- and
receptors-coding genes for BAIBA and GABA, as shown in Supplementary Table 6.
All the GWAS summary data were mapped to hg19 human reference genome
downloaded from UCSC genome browser (http://hgdownload.cse.ucsc.edu/
goldenPath/hg19/database/). A gene with an adjusted p-value FDR < 0.05 was
considered significant.
Statistics analysis and reproducibility. Data are presented as mean ± SD of all
samples in multiple experiments. Comparison analysis was performed using two-
tailed Student’s t-test analysis for two-group comparisons, or one-way ANOVA
with Tukey’s post-Hoc test (α= 0.05) for multiple-group comparisons. Significant
outliers in a univariate data set were detected using Grubb’s test (α= 0.05) in
comparison analysis. Association analysis was performed including: (1) Pearson’s
correlation for 54 older women with or without osteoporotic fractures, (2)
Spearman’s rank correlation for 136 young to middle-aged Caucasian women with
high or low hip BMDs. Additionaly, partial Spearman’s rank correlation, while
controlling for age, BMI, alcohol intake, and/or physical activity, was performed in
136 young to middle-aged Caucasian female cohort for all the physical parameters
and three aminobutyric acids D-BAIBA, GABA, and L-AABA, by using a package
“psych” (version 1.8.12) under R version 3.5.1. p-value ≤ 0.05 was considered as
statistically significant difference.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Ethical approval. Both Creighton University Osteoporosis Research Center and
Tulane University Louisiana Osteoporosis Study have all IRB approvals for their
clinical studies: Creighton University IRB Committee IRB# 07-14738 for Creighton
ORC studies, and Biomedical IRB Committee IRB# 318016 for Tulane LOS studies.
All methods were performed following the relevant policies, regulations and
guidelines for analysing datasets from consenting participants and reporting of the
findings.
Data availability
The data that support the findings of this study are available from the authors on
reasonable request due to the nature of these data (human subjects); and its associated
privacy and HIPPA regulations. See author contributions for specific datasets. All GWAS
summary data for the gene-based association tests have been deposited in the GEFOS
website (http://www.gefos.org/?q=documents). The gene expression quantification by
RNA-Seq for 122 samples will be made available in dbGaP under accession (Accession
code phs001960.v1.p1).
Code availability
The R codes for our analyses are available from the authors on reasonable request, see
author contributions for specific datasets.
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